Research Triangle Park, NC — (Marketwire) – May 27, 2014 – Adherex Technologies Inc. (TSX:AHX, OTC: ADHXF) is responding to a request from the Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange following recent trading activity. Ordinarily, the Company’s policy is not to comment on rumors or speculation. Adherex is not aware of any undisclosed material changes or corporate developments to account for this activity. However, as previously disclosed by Adherex on May 15, 2014, David Freyer, DO, MS, Children’s Hospital Los Angeles, COG ACCL0431 Study Chair, will present, “The Effects of Sodium Thiosulfate (STS) on Cisplatin-induced Hearing Loss: A Report from the Children’s Oncology Group,” in an oral presentation on June 1, 2014, at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The European based SIOPEL 6 study, “A Multicenter Open Label Randomized Phase III Trial of the Efficacy of Sodium Thiosulfate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma,” has been accepted for the “trials in progress” poster session on June 2, 2014. Edward A. Neuwelt, M.D., Professor at Oregon Health & Science University, will present the poster on behalf of the SIOPEL 6 investigators and support team.
The abstracts from both studies are publicly available at http://meetinglibrary.asco.org/.
Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking, including statements or assumptions about regulatory processes and approvals, commercialization, and any other statements regarding the Company’s objectives (and strategies to achieve such objectives), future expectations, beliefs, goals or prospects. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that that necessary approvals by regulatory bodies are not obtained; that regulatory and guideline developments may change; that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals; that clinical results may not be replicated in actual patient settings; that protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors; that the available market for the Company’s products will not be as large as expected; that the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies; that the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2013. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.
For further information, please contact:
Chief Executive Officer
Adherex Technologies Inc.
T: (919) 636-5144